webinar register page

Webinar banner
Development of directly compressible formulations of Sitagliptin hydrochloride and Sitagliptin phosphate
Direct compression is the simplest and most economical way to produce pharmaceutical tablets. Challenging API properties as e.g., poor powder flow or compactibility can limit or even restrict the use of direct compression technology. In this webinar the development of a direct compression formulation of poorly flowing and poorly compactable Sitagliptin hydrochloride and sitagliptin phosphate will be shown and explained.

00:45:00

* Required information
Loading
Register

Speakers

Dr. Tobias Heß
Head of the Innovation & Application Development Group for Pharmaceutical and Medical Products @Chemische Fabrik Budenheim KG
Tobias Hess has more than 13 years of experience in the field of pharmaceutical excipients, their development, production as well as application. Tobias is currently working as the Head of the Innovation & Application Development Group for Pharmaceutical and Medical Products at Chemische Fabrik Budenheim KG. In his position he’s responsible for the development of Budenheim’s pharma product portfolio and the technical customer interaction. He and his team investigate novel excipients and their applications. Prior to working with Chemische Fabrik Budenheim KG, Tobias held senior roles at JRS Pharma and DFE Pharma – also in the fields of excipients for solid dosage forms. In July 2020 Tobias was appointed as “Member of Member of the Complex Excipients Expert Committee” of the United States Pharmacopeia.
Dr. Daniel Zakowiecki
Innovation & Application Development Manager, Pharmaceutical & Medical Products @Chemische Fabrik Budenheim KG
Daniel Zakowiecki is a pharmaceutical professional with over 20 years of experience in the pharmaceutical industry, including 12 years working for the international generic drug manufacturer – Polpharma (Poland) and over 8 years working for the specialty excipients manufacturer – Budenheim (Germany). His background combines chemistry (MSc), pharmaceutical technology (PhD) and project management. Daniel is still active as a scientist and collaborates with various scientific institutions. He is the author/co-author of 40 articles, including 25 published in scientific journals from the Philadelphia List, and co-inventor of 5 inventions, including 2 granted Patents.

Share via Email

All fields are required
 

Switch Time Zone